NCT05694013

Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice

Interventional Platform Study Investigating the Impact of Digital Health Solutions on Health Outcomes and Health-Care Resource Utilization in Participants Receiving Systemic Treatment in Clinical Practice

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the clinical impact and utility of digital health solutions (DHS) on health outcomes and health-care resource utilization in people receiving systemic anti-cancer treatment (approved or non-approved) in clinical practice.

Conditions

• Cancer

Interventions

Type	Name	Description
DEVICE	Roche DPM Module	Participants will be trained in the use of the Roche DPM Module, which they will use alongside local SOC support
DRUG	Atezolizumab SC	Participants will receive atezolizumab SC for 16 cycles (cycle length = 21 days)
OTHER	Local SOC support	Participants will receive local SOC support

Timeline

• Start date: 2023-02-27
• Primary completion: 2024-06-30
• Completion: 2024-06-30
• First posted: 2023-01-23
• Last updated: 2025-10-22
• Results posted: 2025-10-22

Locations

14 sites across 5 countries: Australia, Austria, Germany, Spain, Switzerland